钐新药制剂在肿瘤病理方面的研究与应用
Samarium Drug Preparation Research and Application in Tumor Pathology

作者: 要瑞丽 :中泰财邦(天津)生物技术有限公司,天津;

关键词: 钐制剂骨代谢紊乱骨转移153Sm-EDTMPSamarium Preparations Metabolic Disorder of Bone Bone Metastases 153Sm EDTMP

摘要:
目前医学上主要以放疗,化疗、激素治疗以及阿片类镇痛剂来缓解癌症骨转移的疼痛。体外放射治疗用于局部或区域性病灶有一定疗效,但它有下列局限性。钐制剂为近年来抗癌药物新型制剂,在药理、毒理、致突变、药动力和临床研究,对骨组织有极强的亲和力,能在给药后很快富集于骨交换区域。药理实验表明,本品在小鼠血液中很快消除,主要分布于骨基质的生长区域,尤其是正在矿化中的类骨质层中。通过标记化合物以及放射成像技术检测,在动物体内骨损伤部位的药物分布与正常骨组织分布比率为17。能有效抑制转移性癌细胞或其他骨疾病引起的骨代谢紊乱(即过度成骨活性或破骨活性),同时抑制骨交换中激化因子对痛觉神经的刺激作用。从而达到治疗和镇痛作用。

Abstract: At present, the pain of bone metastasis of cancer is mainly relieved by radiotherapy, chemotherapy, hormone therapy and opioid analgesics in the medicine. External beam radiation therapy for local or regional metastases has a certain effect, but it also has some limitations. SM preparation in recent years’ new anti-cancer drugs in preparation, pharmacology and toxicology, mutation, drug and clinical research, has a strong affinity for bone tissue after administration, can quickly enrich in bone exchange area. Pharmacological experiments showed that SM formulations in mice blood quickly eliminated; the growth area is mainly distributed in the matrix of bone, especially bone mineralization in the layer. The labeled compound and radiation imaging detection, drug distri-bution in vivo in animal bone injury and normal bone tissue distribution ratio is 17. The disorder of bone metabolism caused can effectively inhibit the metastatic cancer cells or other bone diseases, also inhibits bone exchange intensification factor on pain nerve stimulation, and thus plays therapy and analgesic effects.

文章引用: 要瑞丽 (2015) 钐新药制剂在肿瘤病理方面的研究与应用。 世界肿瘤研究, 5, 34-42. doi: 10.12677/WJCR.2015.52006

参考文献

[1] 苏新辉等 (2004) 89SrCl2治疗多发性骨转移癌28例临床疗效分析. 厦门市科学技术协会第四届青年学术年会论文集.

[2] 张锦林, 顾红兵 (2010) 芬太尼透皮贴联合唑来膦酸治疗恶性肿瘤患者骨转移性疼痛. 山西医药杂志, 2, 158- 159.

[3] 唐谨等 (1994) 153Sm-EDTMP治疗多发性骨转移癌临床研究. 中华核医学杂志, 4, 211.

[4] 谭天秩等 (1995) 153Sm-EDTMP治疗多发性骨转移癌的临床观察. 中华核医学杂志, 1, 23.

[5] 蒋宁一 (2001) 放射性核素治疗骨转移癌的研究进展. 同位素, 2, 107.

[6] 安敏霞等 (1998) 1997年美国FDA批准的新药. 中国新药杂志, 2, 1-2.

[7] 樊卫等 (1997) 153Sm-EDTMP治疗鼻咽癌骨转移的近期疗效. 癌症, 4, 291.

[8] 郑容等 (1998) 153Sm-EDTMP治疗乳腺癌多发性骨转移的临床应用. 中华核医学杂志, 4, 240.

[9] 敬开瑜等 (1997) 骨肿瘤临床诊治学. 中国科技出版社, 北京.

分享
Top